13th Jul 2026 11:41
Ixico - London-based medical research company, focused on analysing trial data using neuroscience imaging and biomarkers - Says the discontinuation of two Huntington's disease programmes by existing clients reduces its contracted order book by around GBP1.5 million over the next two financial years. Ixico notes it secured GBP8.0 million of new Huntington's disease programme awards in the first half and says its order book remains 21% above the end of financial 2025. It adds that programme cancellations are a normal feature of drug development and reiterates recently upgraded guidance for financial 2026 and its outlook for 2027. Read More